Research programme: influenza A H1N1 vaccine - Onxeo

Drug Profile

Research programme: influenza A H1N1 vaccine - Onxeo

Alternative Names: B-032; BA-032

Latest Information Update: 06 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype

Most Recent Events

  • 06 Aug 2015 Research programme: influenza A H1N1 vaccine - Onxeo is available for licensing as of 06 Aug 2015.
  • 06 Aug 2015 Discontinued - Preclinical for Influenza-A virus H1N1 subtype in France (Transmucosal)
  • 02 Sep 2014 Preclinical trials in Influenza-A virus H1N1 subtype in France before September 2014 (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top